Shawn M. Ellerbroek
University of North Carolina at Chapel Hill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shawn M. Ellerbroek.
Methods in Enzymology | 2006
Rafael Garcia-Mata; Krister Wennerberg; William T. Arthur; Nicole K. Noren; Shawn M. Ellerbroek; Keith Burridge
An assay was developed that allows the precipitation of the active pools of Rho-GEFs, Rho-GAPs, or effectors from cell or tissue lysates. This assay can be used to identify GEFs, GAPs, and effectors involved in specific cellular pathways to determine their GTPase specificity and to monitor the temporal activation of GEFs and GAPs in response to upstream signals.
Journal of Oncology | 2012
Yueying Liu; Rebecca J. Burkhalter; Jaime Symowicz; Kim Chaffin; Shawn M. Ellerbroek; M. Sharon Stack
Ovarian cancer metastasizes via exfoliation of free-floating cells and multicellular aggregates from the primary tumor to the peritoneal cavity. A key event in EOC metastasis is disruption of cell-cell contacts via modulation of intercellular junctional components including cadherins. Ascites is rich in lysophosphatidic acid (LPA), a bioactive lipid that may promote early events in ovarian cancer dissemination. The objective of this paper was to assess the effect of LPA on E-cadherin junctional integrity. We report a loss of junctional E-cadherin in OVCAR3, OVCA429, and OVCA433 cells exposed to LPA. LPA-induced loss of E-cadherin was concentration and time dependent. LPA increased MMP-9 expression and promoted MMP-9-catalyzed E-cadherin ectodomain shedding. Blocking LPA receptor signaling inhibited MMP-9 expression and restored junctional E-cadherin staining. LPA-treated cells demonstrated a significant decrease in epithelial cohesion. Together these data support a model wherein LPA induces MMP-9 expression and MMP-9-catalyzed E-cadherin ectodomain shedding, resulting in loss of E-cadherin junctional integrity and epithelial cohesion, facilitating metastatic dissemination of ovarian cancer cells.
Small GTPases | 2012
Christina M. Sloan; Clancy V. Quinn; Justin P. Peters; Janean Farley; Chris Goetzinger; Molly Wernli; Kris A. DeMali; Shawn M. Ellerbroek
RhoA, RhoB and RhoC GTPases are over 85% identical at the amino acid level, with RhoA and RhoC differing at only one residue (43) across the initial two-thirds of their sequences. A putative regulatory distinction between the molecules is their capacity to be uniquely activated by guanine nucleotide exchange factors (GEFs). We hypothesize that variation of amino acid residue 43 between RhoA/B (valine) and RhoC (isoleucine) impacts GEF activity. Direct participation of residue 43 in GEF-catalyzed exchange was confirmed by the observation that mutation of this position to a threonine reduced GEF-catalyzed nucleotide exchange activity in vitro (Vav2, XPLN, GEFT, Dbl and Dbs) and greatly depressed RhoA and RhoC GTP-loading profiles in cell lysates. Using a residue swap approach, substitution of RhoA Val 43 with an Ile was found to significantly promote basal nucleotide exchange activity and enhance GTP-loading in cells. Substitution of Val 43 with an Ile in RhoB negatively affected nucleotide exchange in vitro. Substitution of RhoC Ile 43 with a Val increased GEF-catalyzed exchange in vitro. In addition, RhoC-I43V was more efficacious at driving ovarian cancer cell invasion through matrigrel than wild-type RhoC, RhoC-I43T, wild-type RhoA, RhoA-V43I or RhoA-V43T GTPases. These findings suggest that a divergence between RhoA/B and RhoC at residue 43 impacts basal and GEF-stimulated nucleotide exchange activity.
Small GTPases | 2017
Aditi Patel; Sophia Williams-Perez; Nicole Peyton; Amy Reicks; Justin Buzick; Janean Farley; Sarah Shirar; Shawn M. Ellerbroek
ABSTRACT RhoA and RhoC GTPases are 92% identical but demonstrate unique regulation and function. Phosphorylation of Ser188 has widely been reported to inhibit RhoA activity. RhoC possesses Arg188 in place of Ser188 but retains a canonical upstream PKA recognition sequence. We report here that RhoC-R188S was a PKA substrate in vitro and exhibited less GTP loading compared to wild-type RhoC when expressed in cells. Transiently expressed RhoC was found to be significantly more membrane associated than RhoA. Membrane association of RhoC-R188S and RhoC-R188A were similar to each other and wild-type RhoA, suggesting that Arg188 directly promotes RhoC membrane binding. The positive influence of Arg188 on RhoC membrane association was evident in a constitutively active (Q63L) background. In accordance, RhoA-S188R was significantly more membrane associated than either RhoA or RhoA-S188A. Altogether, these data suggest that swapping residue 188 identity effectively flips the membrane binding profile of wild-type RhoA and RhoC through positive arginine contribution rather than negative phosphoserine regulation.
Journal of Biological Chemistry | 2003
Shawn M. Ellerbroek; Krister Wennerberg; Keith Burridge
Cancer Research | 2001
David A. Fishman; Yueying Liu; Shawn M. Ellerbroek; M. Sharon Stack
Current Biology | 2003
Krister Wennerberg; Marie-Annick Forget; Shawn M. Ellerbroek; William T. Arthur; Keith Burridge; Jeffrey Settleman; Channing J. Der; Steen H. Hansen
Cancer Research | 1999
Shawn M. Ellerbroek; David A. Fishman; Alicia S. Kearns; Lisa M. Bafetti; M. Sharon Stack
Journal of Biological Chemistry | 2002
William T. Arthur; Shawn M. Ellerbroek; Channing J. Der; Keith Burridge; Krister Wennerberg
Journal of Biological Chemistry | 2002
Krister Wennerberg; Shawn M. Ellerbroek; Rong Yu Liu; Antoine E. Karnoub; Keith Burridge; Channing J. Der